The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abnormal Liver Development and Resistance to 2,3,7,8-Tetrachlorodibenzo-p-Dioxin Toxicity in Mice Carrying a Mutation in the DNA-Binding Domain of the Aryl Hydrocarbon Receptor
Open accessAbstract
The aryl hydrocarbon receptor (AHR) is known for its role in the adaptive and toxic responses to a large number of environmental contaminants, as well as its role in hepatovascular development. The classical AHR pathway involves ligand binding, nuclear translocation, heterodimerization with the AHR nuclear translocator (ARNT), and binding of the heterodimer to dioxin response elements (DREs), thereby modulating the transcription of an array of genes. The AHR has also been implicated in signaling events independent of nuclear localization and DNA binding, and it has been suggested that such pathways may play important roles in the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Here, we report the generation of a mouse model that expresses an AHR protein capable of ligand binding, interactions with chaperone proteins, functional heterodimerization with ARNT, and nuclear translocation, but is unable to bind DREs. Using this model, we provide evidence that DNA binding is required AHR-mediated liver development, as Ahr(dbd/dbd) mice exhibit a patent ductus venosus, similar to what is seen in Ahr(-/-) mice. Furthermore, Ahr(dbd/dbd) mice are resistant to TCDD-induced toxicity for all endpoints tested. These data suggest that DNA binding is necessary for AHR-mediated developmental and toxic signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Examination of the Ahrdbd construct in vitro revealed that after ligand binding, it retained the ability to translocate to the nucleus and dimerize with ARNT (Bunger et al., 2008).”
From Rodent Genetic Models of Ah Receptor Signaling (2021) · cites this paper as Bunger et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While extensive studies to explain how the presence of the NeoPGK cassette leads to hypomorphism are lacking, preliminary evidence from multiple alleles in our own laboratory suggest that the presence of the NeoPGK transgene reduces RNA expression from multiple loci, independent of direction or position (Bunger et al., 2008; Bunger et al., 2003; Lin et al., 2008; Walisser, Bunger, Glover, & Brad”
From Rodent Genetic Models of Ah Receptor Signaling (2021) · cites this paper as Bunger et al., 2008
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interestingly, this mutation had an unexpected influence on the neighboring NLS and the construct became constitutively nuclear.”
From Rodent Genetic Models of Ah Receptor Signaling (2021) · cites this paper as Bunger et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Yet, in two-hybrid assays, it was shown to maintain its ligand responsiveness and its capacity to dimerize with ARNT (Bunger et al., 2008).”
From Rodent Genetic Models of Ah Receptor Signaling (2021) · cites this paper as Bunger et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“In keeping with its predicted activity, the Ahrdbd mutant could not activate Cyp1 gene expression or interact with AHREs.”
From Rodent Genetic Models of Ah Receptor Signaling (2021) · cites this paper as Bunger et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Poland, A., & Knutson, J. C. (1982) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.22.040182.002505 · Cited by 2,515
The Aryl Hydrocarbon Receptor Complex
Hankinson, O. (1995) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.35.040195.001515 · Cited by 1,649 · cited 3×
“Upon binding agonists such as TCDD, the AHR translocates from the cytoplasm to the nucleus, where it dimerizes with another bHLH-PAS protein known as the AHR nuclear translocator (ARNT) (Hankinson, 1995).”
BackgroundNeonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene
Tybulewicz, V. L. J., Crawford, C. E., Jackson, P. K., Bronson, R. T., & Mulligan, R. C. (1991) · Cell · doi:10.1016/0092-8674(91)90011-m · Cited by 1,281
Schmidt, J. V., Su, G. H., Reddy, J. K., Simon, M. C., & Bradfield, C. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.13.6731 · Cited by 902
Self-citationFernández‐Salguero, P. M., Hilbert, D. M., Rudikoff, S., Ward, J. M., & Gonzalez, F. J. (1996) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1996.0210 · Cited by 835
Gradin, K., McGuire, J., Wenger, R. H., Kvietikova, I., Whitelaw, M. L., Toftgård, R., Tora, L., Gassmann, M., & Poellinger, L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5221 · Cited by 470
Carver, L. A., & Bradfield, C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.17.11452 · Cited by 428
Self-citationAh Receptor and NF-κB Interactions, a Potential Mechanism for Dioxin Toxicity
Tian, Y., Ke, S., Denison, M. S., Rabson, A. B., & Gallo, M. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.1.510 · Cited by 406
Lahvis, G. P., Lindell, S. L., Thomas, R. S., McCuskey, R. S., Murphy, C., Glover, E., Bentz, M., Southard, J., & Bradfield, C. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190256997 · Cited by 377
Self-citationThe aryl hydrocarbon receptor: studies using the AHR-null mice.
Gonzalez, F. J., & Fernández‐Salguero, P. M. (1998) · PubMed · Cited by 375
Lesions of Aryl-hydrocarbon Receptor–deficient Mice
Fernández‐Salguero, P. M., Ward, J. M., Sundberg, J. P., & Gonzalez, F. J. (1997) · Veterinary Pathology · doi:10.1177/030098589703400609 · Cited by 352
Puga, A., Barnes, S., Dalton, T. P., Chang, C., Knudsen, E. S., & Maier, M. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2943 · Cited by 315
Analysis of the four alleles of the murine aryl hydrocarbon receptor
Poland, A., Palen, D., & Glover, E. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09833-5 · Cited by 303
Self-citationNuclear Localization and Export Signals of the Human Aryl Hydrocarbon Receptor
Ikuta, T., Eguchi, H., Tachibana, T., Yoneda, Y., & Kawajiri, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.5.2895 · Cited by 287
A Direct Interaction between the Aryl Hydrocarbon Receptor and Retinoblastoma Protein
Ge, N.-L., & Elferink, C. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.35.22708 · Cited by 258
Walisser, J. A., Glover, E., Pande, K., Liss, A. L., & Bradfield, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504757102 · Cited by 234
Self-citationAmelioration of TCDD-induced teratogenesis in aryl hydrocarbon receptor (AhR)-null mice
Peters, J., Narotsky, M. G., Elizondo, G., Fernández‐Salguero, P. M., Gonzalez, F. J., & Abbott, B. D. (1999) · Toxicological Sciences · doi:10.1093/toxsci/47.1.86 · Cited by 232
Cross-talk between the Aryl Hydrocarbon Receptor and Hypoxia Inducible Factor Signaling Pathways
Chan, W. K., Yao, G., Gu, Y.-Z., & Bradfield, C. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.12115 · Cited by 221
Self-citationBunger, M. K., Moran, S. M., Glover, E., Thomae, T. L., Lahvis, G. P., Lin, B. C., & Bradfield, C. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209594200 · Cited by 215
Self-citationCharacterization of the Ah Receptor-associated Protein, ARA9
Carver, L. A., LaPres, J. J., Jain, S. R., Dunham, E. E., & Bradfield, C. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.50.33580 · Cited by 207
Self-citationEnan, E. E., & Matsumura, F. (1996) · Biochemical Pharmacology · doi:10.1016/s0006-2952(96)00566-7 · Cited by 197
Reversible arrest of growth in G1 of an established fibroblast line (3T3)
Nilausen, K., & Green, H. (1965) · Experimental Cell Research · doi:10.1016/0014-4827(65)90306-x · Cited by 187
Lahvis, G. P., Pyzalski, R. W., Glover, E., Pitot, H. C., McElwee, M. K., & Bradfield, C. A. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.008888 · Cited by 168
Self-citationJain, S., Dolwick, K. M., Schmidt, J. V., & Bradfield, C. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)31725-3 · Cited by 164
Self-citationCyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism.
Liang, H. C., Li, H., McKinnon, R. A., Duffy, J., Potter, S. S., Puga, A., & Nebert, D. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1671 · Cited by 159
Berghard, A., Gradin, K., Pongratz, I., Whitelaw, M. L., & Poellinger, L. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.677 · Cited by 155
ahr null alleles: distinctive or different?
Lahvis, G. P., & Bradfield, C. A. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00134-8 · Cited by 152
Self-citationZaher, H., Fernández‐Salguero, P. M., Letterio, J. J., Sheikh, M. S., Fornace, A. J., Roberts, A. B., & Gonzalez, F. J. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.2.313 · Cited by 151
Schmidt, J. V., Carver, L. A., & Bradfield, C. A. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80668-1 · Cited by 146
Self-citationPostlind, H., Vu, T., Tukey, R. H., & Quattrochi, L. C. (1993) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1993.1031 · Cited by 145
Photoaffinity labeling of the Ah receptor.
Poland, A., Glover, E. A., Ebetino, F. H., & Kende, A. S. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)84570-2 · Cited by 133
Self-citationNeonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2.
Pineau, T., Fernández‐Salguero, P. M., Lee, S. S. T., McPhail, T., Ward, J. M., & Gonzalez, F. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.5134 · Cited by 108
Pollenz, R. S., Davarinos, N. A., & Shearer, T. P. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.6.1127 · Cited by 104
Bacsi, S. G., & Hankinson, O. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.15.8843 · Cited by 77
Poland, A., Glover, E., & Bradfield, C. A. (1991) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10876-6 · Cited by 76 · cited 1×
“All western blot analyses, gel-shift, and photoaffinity labeling experiments were performed essentially as described (Carber and Bradfield, 1997; Chan et al., 1999; Jain et al., 1994; Poland et al., 1991, 1986, 1994).”
MethodSelf-citationCharacterization of Hepatoportal Microvascular Dysplasia in a Kindred of Cairn Terriers
Schermerhorn, T., Dykes, N. L., Rowland, P. H., Yeager, A. E., Erb, H. N., Oberhansley, K., & Bonda, M. (1996) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.1996.tb02053.x · Cited by 71
Blankenship, A. L., & Matsumura, F. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.4.667 · Cited by 58
Molecular Characterization of the Murine Ahr Gene
Schmidt, J. V., Carver, L. A., & BradfieldS, C. A. (1993) · Cited by 39
Buters, J., Doehmer, J., & Gonzalez, F. J. (1999) · Drug Metabolism Reviews · doi:10.1081/dmr-100101929 · Cited by 29
Hepatic Fibrosis in Ahr-/- Mice
McDonnell, W. M., Chensue, S. W., Askari, F. K., & Moseley, R. H. (1996) · Science · doi:10.1126/science.271.5246.223b · Cited by 13
Flagged first, then by citations
Cited by
Sorted by citations
The aryl hydrocarbon receptor: multitasking in the immune system
Stockinger, B., Meglio, P. D., Gialitakis, M., & Duarte, J. H. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120245 · Cited by 909
Denison, M. S., Soshilov, A. A., He, G., DeGroot, D. E., & Zhao, B. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr218 · Cited by 748
DiNatale, B. C., Murray, I. A., Schroeder, J. C., Flaveny, C. A., Lahoti, T. S., Laurenzana, E. M., Omiecinski, C. J., & Perdew, G. H. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq024 · Cited by 651
The aryl hydrocarbon receptor: a perspective on potential roles in the immune system
Stevens, E. A., Mezrich, J. D., & Bradfield, C. A. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03054.x · Cited by 425
Self-citationOmiecinski, C. J., Heuvel, J. P. V., Perdew, G. H., & Peters, J. M. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq338 · Cited by 385
Metadata
- Authors
- Bunger, M. K., Glover, E., Moran, S. M., Walisser, J. A., Lahvis, G. P., Hsu, E. L., & Bradfield, C. A.
- Affiliations
- University of Wisconsin–Madison (US)
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-07-27
- Volume
- 106
- Issue
- 1
- Pages
- 83-92
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- PMC
- PMC2563146
- OpenAlex
- W2148529156
- Cited by
- 139
- References
- 40
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 1 · 2023: 5 · 2022: 4 · 2021: 9 · 2020: 3 · 2019: 7 · 2018: 4 · 2017: 9 · 2016: 6 · 2015: 4 · 2014: 12 · 2013: 12 · 2012: 7
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Toxicological Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (CA014520)
- National Cancer Institute (T32CA009135, P01CA022484, P30CA014520)
- National Institute of Environmental Health Sciences (R01ES013566, F32ES005877, R01-ES-013566-01)
- Topics
- Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Toxic Organic Pollutants Impact
- Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Effects and risks of endocrine disrupting chemicals
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- aryl hydrocarbon receptor, 2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD toxicity, liver development, patent ductus venosus, dioxin response element, mouse model
- MeSH terms
- Polychlorinated Dibenzodioxins, Animals, Carcinogens, Environmental, Carrier Proteins, Cleft Palate, DNA, Fetal Proteins, Hydronephrosis, Liver, Male, Mice, Mutant Strains, Microtubule-Associated Proteins, Portal Vein, Thymus Gland, Transfection, Signal Transduction, 3T3 Cells, Receptors, Aryl Hydrocarbon, Gene Expression Regulation, Developmental, Cytochrome P-450 CYP1A1, Response Elements, Mice, Basic Helix-Loop-Helix Proteins, Basic Helix-Loop-Helix Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
